Botanix News Hub
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Welcome to our home for news – the latest headlines, all in one place. Click through to view a selection of our media coverage, industry news, videos and more.
Capital Raise Update
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix has announced it has now closed the first tranche of its anticipated $7.5 million placement to new and existing institutional and sophisticated investors.
The second tranche of the Placement is an issue of New Shares to Botanix directors, who have committed to subscribe for a total of $0.5 million of New Shares, which is subject to shareholder approval.
Click here to view ASX release
$7.5m Capital Raise
/in ASX Releases, Featured, Latest News /by Haley ChartresBotanix has today announced it has received strong commitments to raise $7.5m through a placement to Australian and international institutions and sophisticated investors.
Funds will support the development of the Company’s lead asset – Sofpironium Bromide (SB) – a novel dermatology asset with positive Phase 3 data to treat primary axillary hyperhidrosis, a medical condition which results in excessive underarm sweating.
This will include support for the FDA approval process and preparation for commercial launch. The New Drug Approval (NDA) filing with the FDA remains on track for submission this quarter with a 12-month review process.
Click here to view ASX release
Research Report by Euroz Hartleys – 17 August 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to advise that leading adviser Euroz Hartleys has released an analysis outlining the strong market opportunities for our most recent asset acquisition, Sofpironium Bromide.
Within the report, analyst Seth Lizee commented:
“Sofpironium Bromide’s target patient population is estimated to be ~3.7 million people in the United States, equal to the estimated number of patients with severe axillary hyperhidrosis seeking treatment…Even modest market penetration can translate into significant revenues.”
Read the full report.
Euroz Hartleys Report | 7 July 22
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the release of the Company announcement that the FDA filing timeline for Sofpironium Bromide had been accelerated.
Click here to view the report.
Euroz Hartleys Report | 22 June 2022
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a research report from leading stockbroking firm, Euroz Hartleys, following the acquisition of our dermatology asset Sofpironium Bromide.
Click here to view the report.
Euroz Hartleys Report | 4 May
/in Featured, Latest News, News /by Haley ChartresBotanix (ASX:BOT) is pleased to share a Quick Comment research report from leading stockbroking firm, Euroz Hartleys, following the acquisition of our dermatology asset Sofpironium Bromide.
Click here to view the report.